Treatment with temozolomide and ibrutinib in recurrent/refractory primary (pcnsl) and secondary cns lymphoma (scnsl) - Université de Lille
Article Dans Une Revue European Journal of Haematology Année : 2021

Treatment with temozolomide and ibrutinib in recurrent/refractory primary (pcnsl) and secondary cns lymphoma (scnsl)

Fichier non déposé

Dates et versions

hal-03367699 , version 1 (06-10-2021)

Identifiants

Citer

Loic Renaud, Jean-Baptiste Bossard, Benjamin Carpentier, Louis Terriou, Nathalie Cambier, et al.. Treatment with temozolomide and ibrutinib in recurrent/refractory primary (pcnsl) and secondary cns lymphoma (scnsl). European Journal of Haematology, 2021, European Journal of Haematology, 107 (3), pp.370-373. ⟨10.1111/ejh.13667⟩. ⟨hal-03367699⟩

Collections

UNIV-LILLE
45 Consultations
0 Téléchargements

Altmetric

Partager

More